Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
$45.73
-1.1%
$49.57
$22.01
▼
$72.36
$1.43B0.7405,292 shs483,756 shs
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
$27.44
-3.9%
$31.25
$27.23
▼
$43.73
$5.07B0.362.19 million shs1.45 million shs
GRAIL, Inc. stock logo
GRAL
GRAIL
$105.60
-8.9%
$121.96
$41.50
▼
$166.48
$5.46B2.86936,290 shs792,617 shs
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$60.97
-4.0%
$63.95
$58.80
▼
$90.87
$5.29B0.521.09 million shs738,544 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
0.00%-0.43%-0.77%-22.52%+36.75%
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
0.00%-9.76%-3.25%-24.58%-14.85%
GRAIL, Inc. stock logo
GRAL
GRAIL
0.00%-4.57%-1.63%+65.68%+45.54%
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
0.00%-2.98%+7.17%-12.88%-15.68%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
$45.73
-1.1%
$49.57
$22.01
▼
$72.36
$1.43B0.7405,292 shs483,756 shs
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
$27.44
-3.9%
$31.25
$27.23
▼
$43.73
$5.07B0.362.19 million shs1.45 million shs
GRAIL, Inc. stock logo
GRAL
GRAIL
$105.60
-8.9%
$121.96
$41.50
▼
$166.48
$5.46B2.86936,290 shs792,617 shs
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$60.97
-4.0%
$63.95
$58.80
▼
$90.87
$5.29B0.521.09 million shs738,544 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
0.00%-0.43%-0.77%-22.52%+36.75%
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
0.00%-9.76%-3.25%-24.58%-14.85%
GRAIL, Inc. stock logo
GRAL
GRAIL
0.00%-4.57%-1.63%+65.68%+45.54%
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
0.00%-2.98%+7.17%-12.88%-15.68%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
2.69
Moderate Buy$75.6765.46% Upside
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
2.78
Moderate Buy$53.5795.23% Upside
GRAIL, Inc. stock logo
GRAL
GRAIL
2.33
Hold$128.8021.97% Upside
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
2.73
Moderate Buy$99.2362.75% Upside

Current Analyst Ratings Breakdown

Latest ANAB, GRAL, COGT, and PTCT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/10/2026
GRAIL, Inc. stock logo
GRAL
GRAIL
Boost Price TargetNeutral$74.00 ➝ $130.00
11/9/2026
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
Boost Price TargetBuy$55.00 ➝ $56.00
11/5/2026
GRAIL, Inc. stock logo
GRAL
GRAIL
Boost Price TargetSector Perform$84.00 ➝ $100.00
11/4/2026
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
Reiterated RatingSell (E+)
11/2/2026
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
Boost Price TargetBuy$108.00 ➝ $109.00
10/30/2026
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
Boost Price TargetBuy$90.00 ➝ $95.00
10/30/2026
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
Boost Price TargetOverweight$109.00 ➝ $112.00
10/30/2026
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
Boost Price TargetSector Perform$75.00 ➝ $77.00
10/20/2026
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
Set Price Target$106.00
10/16/2026
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
Initiated CoverageHold$62.00
10/15/2026
GRAIL, Inc. stock logo
GRAL
GRAIL
Reiterated RatingSell (D-)
(Data available from 11/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
$234.60M5.83N/AN/A$1.34 per share34.13
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
N/AN/AN/AN/A$2.59 per shareN/A
GRAIL, Inc. stock logo
GRAL
GRAIL
$147.17M32.26N/AN/A$54.57 per share1.94
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$1.73B2.94$8.44 per share7.22($2.29) per share-26.62
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-$13.23M$4.96N/A18.90N/A96.30%-14.28%-1.03%N/A
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
-$328.94M-$2.25N/AN/AN/AN/A-79.74%-45.67%N/A
GRAIL, Inc. stock logo
GRAL
GRAIL
-$408.35M-$9.50N/AN/AN/A-243.80%-16.13%-14.38%N/A
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$682.64M-$1.40N/A21.934.65-9.17%N/A-0.10%N/A

Latest ANAB, GRAL, COGT, and PTCT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/12/2026Q1 2027
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-$1.84$0.11+$1.95$0.11$25.56 million$30.27 million
11/5/2026Q3 2026
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
-$0.5636-$0.59-$0.0264-$0.59$7.21 millionN/A
11/4/2026Q3 2026
GRAIL, Inc. stock logo
GRAL
GRAIL
-$2.45-$2.21+$0.24-$2.21$44.21 million$37.54 million
10/29/2026Q3 2026
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$0.1434-$0.62-$0.7634-$0.62$306.43 million$357.81 million
9/21/2026Q2 2026
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-$0.4650$5.11+$5.5750$5.11$14.06 million$27.49 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
N/AN/AN/AN/AN/A
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
N/AN/AN/AN/AN/A
GRAIL, Inc. stock logo
GRAL
GRAIL
N/AN/AN/AN/AN/A
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
N/A
7.58
7.58
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
0.50
10.99
13.57
GRAIL, Inc. stock logo
GRAL
GRAIL
N/A
8.93
8.93
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
N/A
3.27
3.13

Institutional Ownership

CompanyInstitutional Ownership
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
N/A
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
N/A
GRAIL, Inc. stock logo
GRAL
GRAIL
N/A
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
31.50%
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
6.59%
GRAIL, Inc. stock logo
GRAL
GRAIL
1.83%
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
5.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
10429.90 million20.37 millionOptionable
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
258173.99 million162.53 millionOptionable
GRAIL, Inc. stock logo
GRAL
GRAIL
91044.96 million44.14 millionOptionable
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
99183.54 million79.12 millionOptionable

Recent News About These Companies

PTC Therapeutics Earnings Call Highlights Sephience Growth

New MarketBeat Followers Over Time

Media Sentiment Over Time

AnaptysBio stock logo

AnaptysBio NASDAQ:ANAB

$45.73 -0.52 (-1.12%)
Closing price 04:00 PM Eastern
Extended Trading
$47.28 +1.55 (+3.38%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Cogent Biosciences stock logo

Cogent Biosciences NASDAQ:COGT

$27.44 -1.12 (-3.92%)
Closing price 04:00 PM Eastern
Extended Trading
$27.69 +0.25 (+0.91%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

GRAIL stock logo

GRAIL NASDAQ:GRAL

$105.60 -10.29 (-8.88%)
Closing price 04:00 PM Eastern
Extended Trading
$107.00 +1.40 (+1.33%)
As of 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

PTC Therapeutics stock logo

PTC Therapeutics NASDAQ:PTCT

$60.97 -2.52 (-3.97%)
Closing price 04:00 PM Eastern
Extended Trading
$60.90 -0.06 (-0.11%)
As of 07:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.